Status:

COMPLETED

A Multi-center Study of Spherule-Derived Coccidioidin

Lead Sponsor:

Nielsen BioSciences, Inc.

Collaborating Sponsors:

Sr Consultants Inc.

Conditions:

Coccidioidomycosis

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

Adult volunteers were skin tested with 1.27 ug spherule-derived coccidioidin. The skin test antigen was evaluated in three different populations of adult volunteers to determine the safety and efficac...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Good Health (absence of active medical disease)
  • Meets criteria specific to population groups:
  • Coccidioidomycosis Group:
  • History of coccidioidomycosis of at least 45 days duration confirmed by roentgenograph serologic or mycologic findings
  • Histoplasmosis Group:
  • History of pulmonary histoplasmosis
  • Naive Control Group:
  • Lifetime residence in the states of WA, OR, ID, or MT
  • Never employed as an agricultural worker
  • Serology negative for C.immitis antibodies
  • Exclusion Criteria (All Groups):
  • Active medical disease
  • Alcohol abuse or illicit drug use
  • Influenza-like illness within the past 4 weeks
  • Immunizations within the past 4 weeks
  • Current atopic or contact dermatitis, psoriasis, erythema nodosum, urticaria
  • Current treatment with corticosteroids, cytotoxic or immunosuppressive drugs
  • Immunodeficiency disease
  • HIV infection
  • Previous skin test with coccidioidin or SD Coccidioidin
  • Pregnant or lactating
  • Adverse reaction to thimerosal
  • Adverse reaction to Candida or Trichophyton skin test antigens
  • Coccidioidomycosis Group:
  • Current cavitary or disseminated coccidioidomycosis
  • History of histoplasmosis, or blastomycosis
  • Histoplasmosis Group:
  • History of coccidioidomycosis or blastomycosis
  • Naive Control Group:
  • History of coccidioidomycosis, histoplasmosis, blastomycosis
  • Travel for more than 30 days in designated areas of CA, AZ, NV, UT, NM, TX and Mexico, Central and South America. Travel for more than 7 days in restricted areas of CA, AZ and TX.

Exclusion

    Key Trial Info

    Start Date :

    May 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2007

    Estimated Enrollment :

    113 Patients enrolled

    Trial Details

    Trial ID

    NCT00690092

    Start Date

    May 1 2005

    End Date

    September 1 2007

    Last Update

    October 29 2013

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Health Sciences Center AVAHCS, Univ. of Arizona

    Tucson, Arizona, United States, 85723

    2

    Kern Facility Medical Group

    Bakersfield, California, United States, 93306

    3

    Blair Clinic

    Blair, Nebraska, United States, 68001

    4

    Spokane Allergy and Asthma Center

    Spokane, Washington, United States, 99204